Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-seven approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and forty-two supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 84 |
| Ingredients: | 84 |
| NDAs: | 97 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | LAMIVUDINE AND ZIDOVUDINE | lamivudine; zidovudine | TABLET;ORAL | 077411-001 | Sep 7, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipla Ltd | CARBOPLATIN | carboplatin | INJECTABLE;INJECTION | 077383-001 | Jan 27, 2006 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cipla | CELECOXIB | celecoxib | CAPSULE;ORAL | 207446-003 | Sep 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipla | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 217987-001 | Dec 6, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1419152 | C 2012 016 | Romania | ⤷ Sign Up | PRODUCT NAME: COMBINATIE DE RILPIVIRINA SI TOATE FORMELE ECHIVALENTETERAPEUTIC ALE ACESTEIA CUM AR FI SARURILE DE ADITIE ALE RILPIVIRINEI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREARILPIVIRINEI CU ACIDUL CLORHIDRIC, SI TENOFOVIR, IN PARTICULAR FUMARAT DE TENOFOVIRDISOPROXIL; NATIONAL AUTHORISATION NUMBER: EU/1/11/737/001, EU/1/11/737/002; DATE OF NATIONAL AUTHORISATION: 20111128; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/737/001, EU/1/11/737/002; DATE OF FIRST AUTHORISATION IN EEA: 20111128 |
| 1507558 | C300528 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705 |
| 0481754 | 91275 | Luxembourg | ⤷ Sign Up | CERTIFICATE TITLE: ENTECAVIR ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BARACLUDE); FIRST REGISTRATION: 20060626 |
| 1663240 | 122016000109 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, Z.B. EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN. EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
